Saturday, March 03, 2018 6:43:27 AM
So chance of immediate collaboration or BO is low - KTOV is so small that they cannot market the product.
One possibility I see is - TEVA already has approval to sell generic Celebrex in US since 2014 - they may like to buy this product license and combine as a variant of Celebrex for sub-population. This and Israeli connection can help KTOV to cut a deal - however with Teva’s problems - not sure we can expect any significant deal.
The co market cap is $28 million - so Teva can buy them out at just 56 to $84 million (really cheap) to take out competition. That will give 2 to 2.5 times current price - I will be more than happy to come out at that price.
Do not see much potential for appreciation
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM